Replies to post #35162 on RespireRx Pharmaceuticals Inc (RSPI)

[jerrydylan]

By the way, anyone who wishes to send me negative vibes....you go immediately on ignore, I am sorry you need to put me down and it speaks a volume to your immaturity. Please do the same with me.

[gfp927z]

Jerry, Thanks. So I assume someone other than Samyang, and not a pharma. Instead, it would presumably be a private investment outfit/private equity who will get a good size chunk of the company in return? That would make some sense, since raising money that way could be quicker than doing a deal for ex-US ADHD rights with a pharma (and an ex-US ADHD pharma deal might not provide enough in upfronts anyway).

As for SA, your sources indicate the delay is due to the complexity of the data, and a consultant's need for a software program to analyze it? Having to hire an SA consultant to help with the analysis would make sense.

Thanks for the info.

[enemem]

I don't get what you're writing. Is it your impression that the private investors are demanding a say in the ADHD trial design, or that the amount of money they foresee getting will determine the trial design? If it's the latter, that sounds penny-wise, pound-foolish. At this stage in the game, trying to establish efficacy of their lead compound in what is effectively their last real chance at viability on the cheap is completely stupid.

[bladerunner1717]

Jerry,

I don't see why this has to be so complicated, i.e. bringing in an equity partner at this stage. A partnership could be done for CX1739 with enough upfronts to get through a Phase II in ADHD, then the partner takes over for further trials, if Phase II proves successful. This happens all the time.

I don't see why you are so insistent on an equity partner here, when CORX now has a molecule, 1739, that they can outlicense that has potential efficacy in SA, schizo, depression, RD and ADHD.


Bladerunner